Amgen Gets FDA Priority Review For Lung Cancer Treatment

By Ben Glickman

Amgen has received priority review status from the Food and Drug Administration for its biologics license application for a small cell lung cancer treatment.

The Thousand Oaks, Calif.-based pharmaceutical company will get an answer from the FDA on its application in six months, instead of the typical 10 months.

Amgen's BLA is for tarlatamab, a treatment for advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.

The application is based on the results from a Phase 2 study.

Write to Ben Glickman at [e-mail]

(END) Dow Jones Newswires

12-13-23 1625ET